Collection of research highlights now available

A collection of all IMPRiND research highlights is now available for download. This document is a journey through the research results of the project over the last five years.

New scientific consensus has been established by the Cryo-EM characterisation of tau and α-synuclein filaments isolated or amplified from human brains. This work has led to a structure-based stratification of tauopathies and improved standards for the development of ligands or therapeutics (e.g. PET ligands, antibody immunotherapies or anti-aggregation molecules).

Importantly, the consortium has used highly characterized seeds and readouts of seeded aggregation to complete CRISPR-based and siRNA screens and identified modifiers of α-synuclein and tau aggregation in cell lines and primary neurons. These screens will become publicly available upon completion of the project and provide a rich source of data for Industry and academic partners interested in drug target discovery and development.

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking ( under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

© 2019 IMPRiND Project – created by SCIPROMPrivacy policy